Welcome to our dedicated page for JUPITER NEUROSCIENCES news (Ticker: JUNS), a resource for investors and traders seeking the latest updates and insights on JUPITER NEUROSCIENCES stock.
Jupiter Neurosciences, Inc. develops JOTROL™, a patented resveratrol-based platform used in its clinical-stage neuroinflammation pipeline and Nugevia™ consumer longevity products. Company news centers on CNS and rare-disease development, including Parkinson’s disease work, and on commercialization of Nugevia formulations for mitochondrial support, cognitive health and skin vitality.
Recurring updates also cover investor-conference presentations, practitioner and wellness-channel initiatives, advisory-board additions, financing arrangements tied to convertible notes and a standby equity purchase agreement, and Nasdaq listing-compliance matters affecting its common stock.
Jupiter Neurosciences (NASDAQ: JUNS) has launched its Nugevia™ e-commerce platform, marking its entry into the $8 trillion global longevity market. The company is now accepting pre-orders for three nutraceutical supplements: Nugevia™ GLO, PWR, and MND, with shipping starting Fall 2025.
The products leverage Jupiter's patented JOTROL™ resveratrol delivery platform, which demonstrated a nine-fold increase in bioavailability in Phase I trials. This launch represents a dual-path business strategy, combining CNS therapeutic development with consumer health products. The company has also secured Hall of Fame golfer Annika Sörenstam and NBA legend Chris Webber as brand ambassadors.
Jupiter Neurosciences (NASDAQ: JUNS) has announced NBA Hall of Famer Chris Webber as the second brand ambassador for their Nugevia™ longevity supplement line. The five-time NBA All-Star will promote the company's science-backed supplements built on the JOTROL™ platform, a patented resveratrol-based micellar delivery system.
The product line features three formulations - GLO, MND, and PWR - designed to enhance cellular resilience through synergistic ingredients optimized for absorption. This consumer initiative is part of Jupiter's dual-path strategy, targeting the $8 trillion longevity market by 2030 while supporting their clinical development programs and operational costs.
Jupiter Neurosciences (NASDAQ: JUNS) has launched Nugevia™ MND, a cognitive health supplement combining their proprietary JOTROL™ resveratrol technology with NovaSOL® Curcumin. The product targets the $8 trillion longevity and wellness markets and will be available Fall 2025.
The supplement aims to enhance cognitive performance and neuroprotective health through multiple pathways, including reducing oxidative stress and inflammation. CEO Christer Rosén emphasized the personal significance of the product, citing family experiences with Alzheimer's and Parkinson's diseases.
Nugevia MND represents a strategic move to generate high-margin revenue while complementing Jupiter's pharmaceutical pipeline. The company plans to leverage consumer usage data alongside biomarker data from their upcoming Phase II Parkinson's disease trial to inform future cognitive health programs.
Jupiter Neurosciences (NASDAQ: JUNS) has highlighted the significant advantages of its proprietary JOTROL™ platform over traditional resveratrol formulations. The company's breakthrough demonstrates 9x higher bioavailability compared to conventional resveratrol, without gastrointestinal side effects at therapeutic doses.
JOTROL™ has shown ability to cross the blood-brain barrier and is advancing to Phase IIa trials for Parkinson's Disease. The platform's intellectual property is secured through 2036 across major markets. Jupiter plans to launch its Nugevia™ consumer product line in Q3 2025, featuring formulations for cognitive health, mitochondrial energy, and skin vitality.
Jupiter Neurosciences (NASDAQ: JUNS), a clinical-stage pharmaceutical company developing JOTROL™, has successfully regained compliance with Nasdaq's minimum bid price requirement. The company's stock maintained an average closing price of at least $1.00 for 13 consecutive trading days from June 18 to July 8, 2025.
The compliance confirmation was received on July 9, 2025, from Nasdaq's Listing Qualifications Department, effectively resolving the previous listing concern. Jupiter's shares are now fully compliant with Rule 5550(a)(2), and Nasdaq has closed the matter.
Jupiter Neurosciences (NASDAQ: JUNS) has announced the launch of Nugevia™ PWR, a mitochondrial health supplement designed to enhance cellular energy, endurance, and recovery. The product leverages the company's proprietary JOTROL™ resveratrol-based platform technology and will be commercially available in Fall 2025.
The supplement combines JOTROL™, which showed a nine-fold increase in resveratrol bioavailability in Phase I trials, with NovaSOL® solubilized CoQ10. The product targets the longevity and wellness markets, projected to reach $8 trillion by 2030. PWR is designed as a two-capsule daily regimen and will join GLO in Jupiter's Nugevia™ product line.
The company positions PWR as a strategic revenue opportunity, aiming to generate high-margin returns to support its therapeutic development programs while addressing growing consumer demand for scientifically validated supplements.
Jupiter Neurosciences (NASDAQ: JUNS) has announced the launch of Nugevia™ GLO, a premium "beauty-from-within" supplement targeting the $8 trillion longevity market. The product combines the company's proprietary JOTROL™ resveratrol delivery technology with NovaSOL® Astaxanthin to enhance skin health at the cellular level.
Set to launch in Fall 2025 through direct-to-consumer e-commerce platforms, GLO is positioned as a high-margin product primarily targeting women over 35. The supplement leverages JOTROL™, which showed a nine-fold increase in resveratrol bioavailability in Phase I trials. The company expects the Nugevia product line to generate significant revenue and support its clinical development programs.
Jupiter Neurosciences (NASDAQ: JUNS) released its first shareholder letter following its December 2024 Nasdaq debut, outlining key 2025 strategic initiatives. The company is advancing JOTROL™, an enhanced resveratrol formulation with 9x improved bioavailability, into a Phase 2a Parkinson's disease trial in Q3 2025.
Key developments include:
- Strategic expansion into the longevity market with consumer product launch planned for Q3 2025
- Pending $16.5M NIH grant decision for MCI/early Alzheimer's Phase II trial
- Partnership with Aquanova AG for consumer-focused longevity products
- Development of JOTROL™ for neurodegenerative diseases and potential synergies with GLP-1 obesity drugs
The company confirmed its JOTROL™ development programs remain tariff-exempt, with only minimal cost impact on upcoming consumer products.